Showing results (71-80 of 369) with videos related to

Sort By:
Pageof 37
European Urology|February 21, 2015
Long-term Safety and Antitumor Activity in the Phase 1-2 Study of Enzalutamide in Pre- and Post-docetaxel Castration-Resistant Prostate CancerCelestia S Higano, Tomasz M Beer, Mary-Ellen Taplin, et al.
Oncology (Williston Park, N.Y.)|August 31, 2002
Prostate-specific antigen as a marker of disease activity in prostate cancerAlan W Partin, Gerald E Hanks, Eric A Klein, et al.
Oncology (Williston Park, N.Y.)|October 17, 2002
Prostate-specific antigen as a marker of disease activity in prostate cancerAlan W Partin, Gerald E Hanks, Eric A Klein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 10, 2005
Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxelDavid B Solit, Yuhong She, Jose Lobo, et al.
The Lancet. Oncology|February 14, 2009
Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial dataHoward I Scher, Xiaoyu Jia, Johann S de Bono, et al.
Molecular Cancer Therapeutics|March 5, 2022
Optimal Strategy and Benefit of Pulsed Therapy Depend On Tumor Heterogeneity and Aggressiveness at Time of Treatment InitiationDeepti Mathur, Bradford P Taylor, Walid K Chatila, et al.
Urology|May 11, 2005
Androgen deprivation for minimal metastatic disease: threshold for achieving undetectable prostate-specific antigenKathleen Beekman, Michael Morris, Susan Slovin, et al.
Urology|October 31, 2006
Persistent prostate-specific antigen expression after neoadjuvant androgen depletion: an early predictor of relapse or incomplete androgen suppressionCharles J Ryan, Alex Smith, Priti Lal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 8, 2005
2-[18F]fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomyHeiko Schöder, Ken Herrmann, Mithat Gönen, et al.
The Lancet. Oncology|November 4, 2006
Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based studyEthan Basch, Alexia Iasonos, Tiffani McDonough, et al.
Pageof 37